Form 4: Pfizer Executive Vice President Lidia Fonseca Reports Stock Appreciation Rights Acquisition

Executive Vice President Lidia Fonseca reports acquisition of stock appreciation rights related to Pfizer common stock.

Summary

• Lidia Fonseca, an Executive Vice President at Pfizer Inc., filed a Form 4 on February 28, 2024, reporting transactions related to stock appreciation rights.
• On February 27, 2024, Fonseca acquired 68,045 stock appreciation rights at a price of $26.89, exercisable on February 27, 2029, and settled in Pfizer common stock.
• Fonseca also acquired 60,124 stock appreciation rights at a price of $26.89, exercisable on February 27, 2031, and settled in Pfizer common stock.
• Following these transactions, Fonseca directly owns 68,045 and 60,124 derivative securities respectively.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating an executive's acquisition of stock appreciation rights. While it can be seen as a positive sign of confidence, it's a routine occurrence.

Positives

• The acquisition of stock appreciation rights by a high-ranking executive could be interpreted as a positive sign of confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The acquisition of stock appreciation rights by an executive may have a minor positive impact on shareholder sentiment.

Key Dates